Search Within

Steven Maron

  1. "GSK Faculty"
Formats
  1. Meeting Abstract (24)
  2. Journal Article (20)
  3. Conference Paper (1)
Groups
  1. Department of Medicine (45)
  2. GSK Faculty (45)
  3. Gastrointestinal Oncology Service (45)
  4. Solid Tumor Oncology Division (45)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (40)
  6. Epidemiology and Biostatistics (40)

More Groups

People
  1. Yelena Janjigian (35)
  2. Nikolaus Schultz (29)
  3. Geoffrey Ku (27)
  4. Laura Tang (20)
  5. David Ilson (18)
  6. Vivian Strong (18)

More People

Years
  1. 2025 (3)
  2. 2024 (9)
  3. 2023 (13)
  4. 2022 (8)
  5. 2021 (7)
  6. 2020 (3)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Clinical Cancer Research (4)
  3. Annals of Oncology (3)
  4. Annals of Surgery (2)
  5. Annals of Surgical Oncology (2)
  6. Cancer Research (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (18)
  2. American Association for Cancer Research (6)
  3. Oxford University Press (4)
  4. Elsevier Inc. (3)
  5. Springer (3)
  6. American Medical Association (2)

More Publishers

Results (45)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • PD-L1 positive esophagogastric (EG) cancer is associated with distinct bacteria
    Meeting Abstract

    Maron, S. B.; Vanderbilt, C.; Sabwa, S.; Bowman, A.; Chatila, W. K.; Tang, L. H.; Strong, V. E.; Molena, D.; Jones, D. R.; Coit, D. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save